The British Business Bank has made a £100million cornerstone commitment to Apposite Healthcare Growth I, a new fund aimed at supporting the expansion of UK-based health technology companies. The move represents the Bank’s largest fund commitment to date, as well as its first investment with specialist healthcare and life sciences investor Apposite Capital.
The scale-up capital shortage
Apposite Healthcare Growth I will focus on backing innovative businesses operating across a range of critical sub-sectors, including:
The new fund was launched to directly address the ongoing shortage of scale-up capital available for UK life sciences companies that are approaching a critical growth inflection point. By investing in companies developing market-leading technologies and services designed to improve patient outcomes, the fund aims to help these businesses compete globally and create highly skilled domestic jobs.
Bridging the funding gap
The £100 million anchor investment aligns closely with the British Business Bank’s broader strategy to create deeper pools of scale-up funding. As the largest investor in UK venture and venture growth capital funds, the Bank frequently makes cornerstone commitments to help funds achieve a successful first close, providing them with the necessary scale to execute their investment strategies effectively.
Currently, the British Business Bank intends to deliver a major step change in its support for UK scale-ups, actively targeting over 60 per cent of its venture and growth investment flow toward this crucial business stage. The institution also aims to support the launch of 10 new-to-market growth-stage funds over the next five years by writing larger cheques to leading fund managers.
Expert perspectives
Christine Hockley, managing director and head of commercial equity funds at the British Business Bank, highlighted the strategic need for this capital injection.
“The UK needs growth stage funding, and the Bank is stepping up to deliver this,” Hockley stated. “Working with the UK’s venture capital community, we are looking to support the creation of growth stage funds capable of writing significant cheques into the next generation of UK unicorns.”
Hockley added that by writing larger cheques and signaling these commitments to institutional investors, the Bank intends to mobilise the private sector and provide these funds with the firepower they require.
Mark Andrews, investment director of funds and life sciences at the British Business Bank, noted the specific difficulties faced by the life sciences sector.
“The need for scale up funding is especially pronounced in life sciences,” Andrews explained. “However, there remains a shortage of later-stage funds, meaning that many promising life sciences companies cannot fulfil their potential in the UK and may embark on premature or sub-optimal exits.”
Backing the next generation
Sam Gray, managing partner at Apposite Capital, views the commitment as a vital catalyst for transformative growth across the sector.
“The UK is home to an extraordinary depth of scientific research, entrepreneurial talent, and innovative companies, yet many businesses face a persistent gap in scale-up funding,” Gray said. “This fund will bridge that gap, enabling high potential companies to accelerate their growth, commercialise transformative technologies, improve health outcomes and support economic growth.”
The move has also garnered strong government support. Peter Kyle, secretary of State for Business and Trade, emphasised that the investment actively delivers on the promise to back the UK’s most ambitious companies.
“This record investment into Apposite Capital delivers on that promise by giving it the financial firepower to support the UK’s most exciting healthcare tech firms scale, develop cutting edge medical products and diagnostics, and improve healthcare right across the country,” Kyle said.